GlassScriptPhysician profile
Cristina Pinal
NPI 1215348248
$2,443.02
in general payments reported to CMS, 2019-2025
22 companies · $940 in 2025
The $940 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $157 · 2021: $352 · 2022: $379 · 2023: $250 · 2024: $139 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $517.02 | 2022-2025 | |
| Amgen INC. | $335.91 | 2020-2025 | Tavneos, Krystexxa |
| Alexion Pharmaceuticals, INC. | $231.31 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $186.74 | 2021-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $177.64 | 2019-2025 | Farxiga |
| Shockwave Medical, INC | $163.05 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Ardelyx, INC. | $121.36 | 2025 | Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $114.82 | 2019-2021 | |
| Travere Therapeutics, INC. | $108.92 | 2025 | |
| Horizon Therapeutics Plc | $71.02 | 2021-2022 | |
| Vifor Pharma, INC. | $70.41 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.51 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $47.55 | 2019-2022 | |
| Novo Nordisk INC | $44.85 | 2025 | Ozempic, Wegovy |
| Abiomed | $41.92 | 2023 | Impella |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $37.00 | 2020 | |
| Ascendis Pharma Endocrinology INC | $23.94 | 2025 | Yorvipath |
| Apellis Pharmaceuticals, INC. | $23.12 | 2025 | |
| Calliditas Therapeutics US INC. | $18.72 | 2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $17.96 | 2025 | Benlysta |
| Nxstage Medical, INC. | $16.89 | 2021 | |
| Scpharmaceuticals INC. | $15.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristina Pinal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.